Redeye provides a more in-depth review of Episurf Medical’s Q3 report.
Gapwaves announced a supply agreement and joint development with Valeo (previously undisclosed Europ...
Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constan...
Doro delivered solid gross and operating margins in the quarter.
Ahead of Cibus' Q3 report, we include the acquisition of eight properties in Denmark and Finland, an...
Redeye maintains its fair value range for Sleep Cycle following the Q3 2024 quarterly report, which ...
Redeye updates on Invisio post Q3-results which were close to our forecast while the order intake wa...
Redeye thinks that Lagercrantz reported another stable quarter in a challenging market.
Redeye takes a positive stance towards Fortnox following a solid Q3 report, with strong net customer...
Redeye strengthens its positive view of Teneo AI following a Q3 report with substantially accelerati...
- OEM and AM challenges to normalise in Q1'25e - '24e-'26e EBIT down 18-3%; 20% CAGR '23-'26e - 30-1...
- ~40% y-o-y order intake growth in Q3 provides visibility - Minor positive estimate revisions - NTM...
- Q3: Sales weaker than expected, but solid margins - We trim sales, but more than offset by a lower...
- Slower recovery, but positive gross margin trend - We lower '24e-'26e adj.
- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj.
